Alcobra to Present Fragile X Study Results at 2013 FRAXA Investigators Meeting

TEL AVIV, ISRAEL, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, announced today that Dr. Patricia Cogram of Neuro-DVI, in conjunction with Alcobra, will present results from the Company's Fragile X mouse study at the FRAXA Investigators Meeting in Southbridge, MA being held from September 29th through October 2nd.

Once the presentation has concluded, a copy of the pre-clinical data will be available on the Company's website http://www.alcobra-pharma.com/events.cfm.

"We look forward to having an opportunity to present our significant study results on the use of MG01CI for the treatment of Fragile X Syndrome to a qualified group of experts," commented Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra Ltd. "Our pre-clinical study using Metadoxine to treat Fragile X showed significant improvement in behavioral outcomes assessed within an animal model."

Dr. Jonathan Rubin, Chief Medical Officer of Alcobra Ltd. added, "This is an excellent opportunity to discuss the potential for MG01CI to treat individuals with Fragile X Syndrome, an area of significant unmet need. We hope these results will result in greater awareness of the research we are doing with MG01CI as well as raise awareness of the range of cognitive dysfunctions in different therapeutic areas that MGO1CI may be able to treat."

Earlier this month, Alcobra announced results from a Fragile X study which showed significant improvement in cognitive and social functioning following treatment with Metadoxine in a valid animal model of Fragile X Syndrome (FMR1 knock-out mouse model). The study was funded in part by the FRAXA Research Foundation.

About the 2013 FRAXA Investigators Meeting

Over 150 researchers will meet in the Southbridge Hotel from September 29th through October 2nd to present and discuss current findings in Fragile X, autism, and related disciplines. The meeting will maximize collaboration among participants to further the mission of finding and implementing viable treatments for Fragile X. Attendees are current or past FRAXA sponsored researchers, along with investigators from academia, the NIH, and pharmaceutical companies such as Alcobra.

About Alcobra Ltd.

Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat cognitive dysfunction, such as Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MG01CI has completed Phase II studies to treat ADHD. The company was founded in 2008 and is headquartered in Tel Aviv, Israel.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Alcobra's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Alcobra could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding the potential for MG01CI to treat individuals with Fragile X Syndrome, creation of greater awareness of the research done with MG01CI and range of cognitive dysfunctions that MG01CI may be able to treat. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Alcobra Ltd.'s registration statement on Form F-1 filed with the Securities and Exchange Commission ("SEC") and in subsequent filings with the SEC. Except as otherwise required by law, Alcobra disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: U.S. Investor Contacts: KCSA Strategic Communications Jeffrey Goldberger / Garth Russell +1 212.896.1249 / +1 212.896.1250 jgoldberger@kcsa.com / grussell@kcsa.com Israel Investor Contact: Investor Relations Ltd. Moran Meir-Beres +011972-3-5167620 moran@km-ir.co.ilSource:Alcobra Ltd.